Sustained-release coating of degradable medicaments coating bracket

Abstract

The invention belongs to a drug release coating of a degradable drug-coated stent of coronary stents in the medicinal material field. The drug release coating is composed of drug for inhibiting thrombosis and tissue hyperplasia and a polymer carrier. The drug can be rapamycin, tacrolimus or paclitaxel, wherein, the polymer carrier in the drug release coating is poly ortho ester (POE). The invention is the drug release coating of the degradable drug-coated stent which is especially applied to coronary interventional operations. With the poly ortho ester used as the carrier, the stent can lead to the long-acting release of the drug coated on the surface of the stent, improve the stability of the drug, achieve more ideal effects of the drug release, prolong the physical activity of the drug and reduce the toxic and side effects of the drug, thereby preventing the occurrence of postoperative inflammation effectively.

Description

technical field [0001] The invention belongs to a coronary stent in the field of medical materials, in particular to a slow-release coating of a degradable drug-coated stent. Background technique [0002] Coronary angioplasty is an important means of treatment of coronary heart disease, the high rate of postoperative restenosis has become the main problem of perplexing coronary heart disease interventional therapy. Drug-coated stent is currently one of the fastest and most effective methods for treating coronary artery stenosis. It achieves the purpose of preventing and inhibiting vascular restenosis by releasing drugs that inhibit thrombosis and tissue proliferation coated on the surface of the stent. . The drug coating coated on the surface of the stent is composed of drugs and polymer carriers that inhibit thrombus formation and tissue proliferation. The use of drug-coated stents can reduce the postoperative restenosis rate from 30% to 40% to less than 10%, but the fina...

AI Technical Summary

Problems solved by technology

[0004] Most of the carriers in the slow-release coating coated on the current biodegradable drug-coated stents are two kinds of polymer carriers, polylactic acid (PLA) and polylactic acid-glycolic acid (PLGA). The carrier has the following disadvantages: 1. PLA and PLGA are highly hydrophilic polymers, which may swell in aqueous solution, and the hydrolysis rate is getting faster and faster, so it is difficult to achieve uniform drug release; 2. PLA and PLGA The product of hydrolysis of this polymer is lactic acid or glycolic acid, which is irritating to cells and easily causes inflammation